IP Library Granted Patent US 9,724,370
Granted Patent B2
US 9,724,370 · App. 14/848,148 · Granted Aug 8, 2017

Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition

Inventors: Scheffer Tseng (Pinecrest, FL); Hua He (Miami, FL); Wei Li (Shenzhen, CN)
Assignee: TISSUETECH, INC.
A61K35/50A61K9/0014A61K9/0048A61K9/0053A61K9/06A61K9/08A61K31/738A61K35/48A61K38/1709A61K38/39A61K38/4886A61L15/40A61L15/44C07K14/4702C07K14/4718C07K14/78C07K14/8114A61L2300/412A61L2300/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,724,370
App. No.
14/848,148
Granted
Aug 8, 2017
Kind
B2
Abstract

Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

Claims (11)

1. A method of preventing or reversing scar formation in a subject in need thereof, comprising administering to the subject a composition comprising a water-soluble extract of amniotic membrane from frozen or previously frozen placenta, wherein the water-soluble extract comprises tumor necrosis factor-stimulated gene 6 (TSG-6), pentraxin (PTX-3), thrombospondin (TSP-1), and cross-linked high molecular weight hyaluronan (HA).

2. The method of claim 1 , wherein the extract further comprises Smad7.

3. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable diluent, excipient, carrier, or combination thereof.

4. The method of claim 3 , wherein the composition is formulated as a non-solid dosage form.

5. The method of claim 3 , wherein the composition is formulated as a solution, drops, suspension, aerosol, paste, spray, ointment, oil, emulsion, cream, lotion, gel, a coated bandage, a patch, sticks, balms, shampoo, or combination thereof.

6. The method of claim 3 , wherein the composition is formulated for ophthalmic administration, systemic administration, or topical administration.

7. The method of claim 3 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjuctival injection, retrobulbar injection, intracameral injection, sub-Tenon's injection, implantation, ocular implantation, ocular insertion, insertion between an eye and eyelid, or insertion in a conjunctival sac.

8. The method of claim 3 , wherein the composition further comprises a penetration enhancer and an aqueous adjuvant.

9. The method of claim 3 , wherein the composition is formulated as a solid dosage form.

10. The method of claim 3 , wherein the composition is formulated for controlled release.

11. The method of claim 1 , wherein the subject has a surgical scar, a wound scar, a scar from a burn, or a scar from a mechanical injury.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FUNDING IV TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0200 →
SECURITY INTEREST Recorded Jun 7, 2024
From: BIOTISSUE HOLDINGS INC.; BIOTISSUE OCULAR INC.; BIOTISSUE SURGICAL INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 067666/0235 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FINANCIAL TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0165 →
CHANGE OF NAME Recorded May 22, 2023
From: TISSUETECH, INC.
To: BIOTISSUE HOLDINGS INC.
Reel/Frame 063713/0329 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - TERM LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 060116/0413 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - REVOLVING LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 060116/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2015
From: BIO-TISSUE, INC.
To: TISSUETECH, INC.
Reel/Frame 036962/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2015
From: TSENG, SCHEFFER; HE, HUA; LI, WEI
To: BIO-TISSUE, INC.
Reel/Frame 036962/0464 →
Continuity (5)
Continuation 13802359 · Mar 13, 2013
Continuation 13453765 · Apr 23, 2012
Continuation 11528902 · Sep 27, 2006
Provisional Application 60720760 · Sep 27, 2005
Related Publication 20160129050A1 · May 12, 2016